Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) FCF Margin (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed FCF Margin for 9 consecutive years, with 19.01% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 747.0% year-over-year to 19.01%, compared with a TTM value of 18.27% through Dec 2025, up 139.0%, and an annual FY2025 reading of 18.27%, up 139.0% over the prior year.
  • FCF Margin was 19.01% for Q4 2025 at Puma Biotechnology, up from 17.8% in the prior quarter.
  • Across five years, FCF Margin topped out at 30.22% in Q3 2022 and bottomed at 58.8% in Q1 2022.
  • Average FCF Margin over 5 years is 8.48%, with a median of 14.06% recorded in 2024.
  • The sharpest move saw FCF Margin plummeted -7476bps in 2022, then soared 6381bps in 2023.
  • Year by year, FCF Margin stood at 9.82% in 2021, then surged by 189bps to 8.77% in 2022, then skyrocketed by 65bps to 14.45% in 2023, then soared by 83bps to 26.49% in 2024, then dropped by -28bps to 19.01% in 2025.
  • Business Quant data shows FCF Margin for PBYI at 19.01% in Q4 2025, 17.8% in Q3 2025, and 26.98% in Q2 2025.